Literature DB >> 11679971

Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA.

M Martinot-Peignoux1, N Boyer, D Cazals-Hatem, B N Pham, A Gervais, V Le Breton, S Levy, C Degott, D C Valla, P Marcellin.   

Abstract

A significant proportion of patients with detectable antibodies to hepatitis C virus have normal serum alanine transaminase levels. Our aim was to study the outcome of this group. Between 1992 and 1999, 135 consecutive anti-HCV-positive patients with persistently normal ALT were followed for 3.6 +/- 2.3 years (0.5 to 8.5 years), 108 had a liver biopsy at inclusion, and 24 had a second liver biopsy 3.5 +/- 1.0 years later. Serum HCV RNA was detectable with PCR in 94 patients (69%) and not detectable in 41 patients (31%). Patients with and without detectable serum HCV RNA had similar epidemiological characteristics. Serum ALT levels and anti-HCV ratio were lower (P =.001), and histological lesions had lower grade and stage in patients without detectable serum HCV RNA (P =.001). Liver HCV RNA was not detectable with PCR in the 12-serum HCV RNA-negative patients tested. During follow-up, all patients without detectable serum HCV RNA remained HCV RNA-negative and kept normal serum ALT; all patients with detectable serum HCV RNA remained HCV RNA-positive, 20 (21%) had a slight fluctuation of serum ALT above the upper limit of normal. No significant changes were observed in the liver lesions of the 24 patients who underwent a second liver biopsy. In anti-HCV-positive patients with persistently normal serum ALT, histological lesions are significantly lower in HCV RNA-negative than in HCV RNA-positive patients. During follow-up, the HCV RNA status of patients remained unchanged; 21% of the patients with detectable serum HCV RNA had slight increase in serum ALT levels, but histological lesions remained stable.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11679971     DOI: 10.1053/jhep.2001.28458

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  24 in total

1.  Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients.

Authors:  M G Rumi; F De Filippi; C La Vecchia; M F Donato; S Gallus; E Del Ninno; M Colombo
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

Review 2.  Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Rosa Zampino; Margherita Macera; Caterina Sagnelli; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

3.  HIV coinfection with hepatitis C and hepatitis B.

Authors:  Jenny O Smith; Richard K Sterling
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

Review 4.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

5.  HIV-HCV Coinfection.

Authors:  Amrita Sethi; Richard K Sterling
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-05

6.  Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines.

Authors:  Naoki Harada; Naoki Hiramatsu; Tsugiko Oze; Ryoko Yamada; Mika Kurokawa; Masanori Miyazaki; Takayuki Yakushijin; Takuya Miyagi; Tomohide Tatsumi; Shinichi Kiso; Tatsuya Kanto; Akinori Kasahara; Masahide Oshita; Eiji Mita; Hideki Hagiwara; Yoshiaki Inui; Kazuhiro Katayama; Shinji Tamura; Harumasa Yoshihara; Yasuharu Imai; Atsuo Inoue; Norio Hayashi; Tetsuo Takehara
Journal:  J Gastroenterol       Date:  2012-09-14       Impact factor: 7.527

7.  Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study.

Authors:  Naoki Hiramatsu; Yuko Inoue; Tsugiko Oze; Nao Kurashige; Takayuki Yakushijin; Kiyoshi Mochizuki; Takuya Miyagi; Tomohide Tatsumi; Shinichi Kiso; Tatsuya Kanto; Akinori Kasahara; Tetsuo Takehara; Masahide Oshita; Eiji Mita; Hideki Hagiwara; Yoshiaki Inui; Kazuhiro Katayama; Shinji Tamura; Harumasa Yoshihara; Yasuharu Imai; Norio Hayashi
Journal:  J Gastroenterol       Date:  2011-08-20       Impact factor: 7.527

8.  Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases.

Authors:  C-K Hui; A Monto; T Belaye; E Lau; T L Wright
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

Review 9.  [Liver biopsy at the intersection of clinical and pathological diagnosis].

Authors:  U Spengler; H-P Fischer
Journal:  Pathologe       Date:  2008-02       Impact factor: 1.011

10.  Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody.

Authors:  Sarah Maylin; Michelle Martinot-Peignoux; Marie-Pierre Ripault; Rami Moucari; Ana Carolina Cardoso; Nathalie Boyer; Nathalie Giuily; Corinne Castelnau; Michelle Pouteau; Tarik Asselah; Marie Hélène Nicolas-Chanoine; Patrick Marcellin
Journal:  Liver Int       Date:  2008-12-09       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.